# Airway Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/airway-therapeutics

- Industry: Biotechnology
- Headquarters: Cincinnati, US
- Website: www.airwaytherapeutics.com
- Total disclosed funding: $4.6M
- Latest round: Series A (Sep 10, 2014)
- Investors on record: 3

## About

Airway Therapeutics, Inc. specializes in developing innovative biologics focused on respiratory and inflammatory diseases, particularly with their lead product, zelpultide alfa, aimed at improving outcomes for vulnerable neonatal patients.Founded in 2011 and headquartered in Cincinnati, US, Airway Therapeutics, Inc. is dedicated to developing treatments for respiratory conditions. The company has raised a total of USD 15.50 mn, with their latest funding round being a Series C in January 2020 amounting to USD 15.50 mn. The company has conducted five deals to date under the leadership of CEO Marc Salzberg.Airway Therapeutics specializes in developing innovative biologics aimed at addressing respiratory and inflammatory diseases, focusing on their flagship product, zelpultide alfa (AT-100). Zelpultide alfa is a recombinant human protein engineered to mimic the endogenous protein hSP-D, designed to reduce inflammation and infection while modulating the immune response, thereby disrupting the cycle of injury and inflammation associated with conditions like bronchopulmonary dysplasia (BPD). This condition affects very preterm infants, with an estimated 200,000 at risk annually in the U.S. and Europe, and approximately 2.5 million globally. Airway Therapeutics targets hospitals, neonatal intensive care units (NICUs), and healthcare providers specializing in pediatric care across North America and Europe, ensuring that their treatments reach the vulnerable populations most in need of effective interventions.The revenue structure of Airway Therapeutics revolves around the commercialization of its biopharmaceutical products, particularly zelpultide alfa, through partnerships and clinical research agreements with hospitals and healthcare institutions. The company may engage in B2B transactions where healthcare providers purchase their products for use in clinical settings. Transactions could include supply agreements for zelpultide alfa tailored specifically for neonatal care and clinical trials involving preterm infants at risk for BPD. Pricing details for the company's products are strategically determined based on factors such as research and development costs, regulatory approvals, and market demand, particularly as they seek to establish zelpultide alfa as a leading therapy in pediatric respiratory care.Airway Therapeutics aims to expand its product line by introducing new therapies addressing critical unmet needs in pediatric respiratory health. They are actively exploring additional markets across Europe and Asia by 2023 to enhance their global footprint. The USD 15.50 mn raised in the Series C funding will support these initiatives by facilitating research and development efforts and broadening their clinical trial capabilities.

## Funding rounds

- Series A, Sep 10, 2014, $4.6M — Queen City Angels, CincyTech, Cincinnati Children's Hospital Medical Center

## Investors

- Queen City Angels (https://capitalatlas.ai/funds/queen-city-angels) — Series A
- CincyTech (https://capitalatlas.ai/funds/cincytech) — Series A
- Cincinnati Children's Hospital Medical Center — Series A